Skip to main content

Table 6 Sensitivity analysis (best estimate)*

From: The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis

 

Potential savings (per inhabitant)

Canada

$146.4 million ($4.68)

France

$95.3 million ($1.61)

Germany

$214.1 million ($2.59)

Norway

$24.1 million ($5.38)

UK

$199.8 million ($3.36)

US

$1 340.6 million ($4.86)

  1. * The proportion of the population treated for hypertension increased to 9.4%, and the proportion of patients with hypertension and cardiovascular disease that can take thiazides increased to 40%